secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0000950170-23-006234
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight Q4 revenue $16.1M (+91% YoY); FY22 revenue $49.0M (+117%); guides FY23 rev $78-83M
--------------------------------------------------------------------------------

- Q4 2022 revenue $16.1M, up 91% YoY; LAL procedure volumes up 208% to 9,123 units; LDD installed base 400 (+94% YoY).
- Full year 2022 revenue $49.0M, up 117% YoY; sold 195 LDDs and 25,284 LALs.
- FY23 revenue guidance $78-83M (59-69% growth); gross margin guidance 52-54% (up from 43.5% in FY22).
- Net loss Q4 $(15.6)M ($0.56 loss per share); adjusted net loss $(12.6)M ($0.45 loss per share).
- Completed public offering of 4.6M shares (including underwriter option) at $12.50/share in Feb 2023, raising ~$57.5M gross.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017023006234/0000950170-23-006234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017023006234/rxst-20230306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer